349 related articles for article (PubMed ID: 22070827)
21. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.
Ono T; Mimuro J; Madoiwa S; Soejima K; Kashiwakura Y; Ishiwata A; Takano K; Ohmori T; Sakata Y
Blood; 2006 Jan; 107(2):528-34. PubMed ID: 16189276
[TBL] [Abstract][Full Text] [Related]
22. Pathophysiology of thrombotic thrombocytopenic purpura.
Tsai HM
Int J Hematol; 2010 Jan; 91(1):1-19. PubMed ID: 20058209
[TBL] [Abstract][Full Text] [Related]
23. [A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)].
Liu F; Lu GY; Dong NZ; Bai X; Su J; Ruan CG
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3190-3. PubMed ID: 16405838
[TBL] [Abstract][Full Text] [Related]
24. ADAMTS13 related markers and von Willebrand factor in plasma from patients with thrombotic microangiopathy (TMA).
Kobayashi T; Wada H; Nishioka N; Yamamoto M; Matsumoto T; Tamaru T; Nomura S; Masuya M; Mori Y; Nakatani K; Nishikawa M; Katayama N; Nobori T
Thromb Res; 2008; 121(6):849-54. PubMed ID: 17900666
[TBL] [Abstract][Full Text] [Related]
25. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F
Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645
[TBL] [Abstract][Full Text] [Related]
26. ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment.
Hori Y; Hayakawa M; Isonishi A; Soejima K; Matsumoto M; Fujimura Y
Transfusion; 2013 Dec; 53(12):3192-202. PubMed ID: 23560518
[TBL] [Abstract][Full Text] [Related]
27. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies.
Crawley JT; Scully MA
Hematology Am Soc Hematol Educ Program; 2013; 2013():292-9. PubMed ID: 24319194
[TBL] [Abstract][Full Text] [Related]
28. Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13.
Tersteeg C; Fijnheer R; Pasterkamp G; de Groot PG; Vanhoorelbeke K; de Maat S; Maas C
Semin Thromb Hemost; 2016 Feb; 42(1):9-17. PubMed ID: 26595154
[TBL] [Abstract][Full Text] [Related]
29. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
Starke R; Machin S; Scully M; Purdy G; Mackie I
Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
[TBL] [Abstract][Full Text] [Related]
30. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission.
Groot E; Fijnheer R; Sebastian SA; de Groot PG; Lenting PJ
J Thromb Haemost; 2009 Jun; 7(6):962-9. PubMed ID: 19548905
[TBL] [Abstract][Full Text] [Related]
31. [Genetic polymorphism of von Willebrand factor (VWF)-cleaving protease, ADAMTS13].
Kokame K
Brain Nerve; 2008 Nov; 60(11):1325-32. PubMed ID: 19069166
[TBL] [Abstract][Full Text] [Related]
32. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
33. TTP and ADAMTS13: When Is Testing Appropriate?
Mannucci PM; Peyvandi F
Hematology Am Soc Hematol Educ Program; 2007; ():121-6. PubMed ID: 18024619
[TBL] [Abstract][Full Text] [Related]
34. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP).
Gerritsen HE; Turecek PL; Schwarz HP; Lämmle B; Furlan M
Thromb Haemost; 1999 Nov; 82(5):1386-9. PubMed ID: 10595623
[TBL] [Abstract][Full Text] [Related]
35. [Changes of ADAMTS13 activity and vWF antigen level in patients with acute myelogenous leukemia and their significance].
Zhang WJ; Han Y; Ma ZN; Wang Q; Tang YQ; Wang J; Su J; Sun AN; Wang ZY; Ruan CG; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1503-7. PubMed ID: 25543464
[TBL] [Abstract][Full Text] [Related]
36. ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.
Peyvandi F; Mannucci PM; Valsecchi C; Pontiggia S; Farina C; Retzios AD
Am J Hematol; 2013 Oct; 88(10):895-8. PubMed ID: 23813910
[TBL] [Abstract][Full Text] [Related]
37. [ADAMTS13, von Willebrand factor specific cleaving protease].
Veyradier A; Coppo P
Med Sci (Paris); 2011 Dec; 27(12):1097-105. PubMed ID: 22192749
[TBL] [Abstract][Full Text] [Related]
38. The potential therapeutic benefit of targeting ADAMTS13 activity.
Eerenberg ES; Levi M
Semin Thromb Hemost; 2014 Feb; 40(1):28-33. PubMed ID: 24338607
[TBL] [Abstract][Full Text] [Related]
39. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction.
Austin SK; Starke RD; Lawrie AS; Cohen H; Machin SJ; Mackie IJ
Br J Haematol; 2008 May; 141(4):536-44. PubMed ID: 18341632
[TBL] [Abstract][Full Text] [Related]
40. [From gene to disease; congenital thrombotic thrombocytopenic purpura due to mutations in the ADAMTS13 gene].
Schiphorst RH; van de Kar NC; van den Heuvel LP
Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2422-4. PubMed ID: 14694551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
